Author(s)

Tsevi Yawovi Mawufemo^1,2, Lagou Amélie Delphine², Tia Weu Mélanie², Coulibaly Pessa Nawo Albert², Cherif Ibrahima², Guei Monlet Cyr², Ackoundou-N’Guessan Kan Clément²

¹Nephrology and Dialysis Department of Teaching Hospital Sylvanus Olympio, University of Lomé, Lomé, Togo.
²Néphrology, Hémodialysis and Organ Transplant Departement of Yopougon Teaching Hospital, University Felix Houphouet Boigny, Abidjan, Cote d’Ivoire.

Background: Viral hepatitis C is a major public health problem in the world. The advent of direct-acting antivirals has revolutionized the taking in charge and prognosis of patients infected with the hepatitis C virus. The interest of this presentation is to draw attention to the problem of therapeutic care posed by viral hepatitis C in kidney transplant patients in C?te d’Ivoire, a country with limited resources where all direct-acting antivirals are not yet available. Patient observation: We report the case of a kidney transplant of 52 years old, chronic bearer of viral hepatitis C virus who after his kidney transplant presented, decompensated active cirrhosis. A treatment based on Sofosbuvir 400 mg/Ledipasvir 90 mg in this patient with genotype 2 for 12 weeks was initiated. A sustained virological response was observed 12 weeks after the end of treatment. Conclusion: Direct-acting antivirals offer the possibility of antiviral C treatment without interferon or ribavirin in cirrhotic renal transplant.

Côte D’Ivoire, Direct-Acting Antivirals, Kidney Transplantation, Viral Hepatitis C

Mawufemo, T. , Delphine, L. , Mélanie, T. , Albert, C. , Ibrahima, C. , Cyr, G. and Kan Clément, A. (2017) Post Hepatitis C Cirrhosis in Sub-Sahara Kidney Transplant, Treated with Sofosbuvir/Ledipasvir: Report of Case and Review of Literature. Open Journal of Nephrology, 7, 95-100. doi: 10.4236/ojneph.2017.74011.